NICE now allows Yescarta in specific cases for large B-cell lymphoma.- Gilead/Kite.
The National Institute for Health and Care Excellence announced that Yescarta (axicabtagene ciloleucel), from Gilead Sciences/Kite Pharma, will be available on the NHS to some adults with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma. This CAR T-cell therapy will be offered to people whose disease has not responded after two or more rounds of chemotherapy or relapsed after a stem cell transplant.
In August 2018, NICE initially rejected the therapy for being too expensive, but since then a commercial deal between NHS England and Gilead group Kite has increased its potential cost effectiveness.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins